Phase II Trial of Erlotinib Plus Concurrent Whole-Brain Radiation Therapy for Patients With Brain Metastases From Non–Small-Cell Lung Cancer

PURPOSE: Brain metastasis (BM) is a leading cause of death from non–small-cell lung cancer (NSCLC). Reasoning that activation of the epidermal growth factor receptor (EGFR) contributes to radiation resistance, we undertook a phase II trial of the EGFR inhibitor erlotinib with whole-brain radiation t...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Welsh, James W., Komaki, Ritsuko, Amini, Arya, Munsell, Mark F., Unger, Wyatt, Allen, Pamela K., Chang, Joe Y., Wefel, Jeffrey S., McGovern, Susan L., Garland, Linda L., Chen, Su S., Holt, Jamie, Liao, Zhongxing, Brown, Paul, Sulman, Erik, Heymach, John V., Kim, Edward S., Stea, Baldassarre
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Clinical Oncology 2013
Assuntos:
Original Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3577951/
https://ncbi.nlm.nih.gov/pubmed/23341526
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.40.1174
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados